Tier 2 — strong
A phase-II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment
Alzheimer's & dementia : the journal of the Alzheimer's Association
2026
22; 7; e71605
Bibliography
- PubMed
- PMID 42478598
- PubMed Central
- PMC13386481
- Funding
- NIH/NIA and NIGMS support; Niagen Bioscience, formerly ChromaDex, supplied NR and placebo.
- Competing interests
- The authors reported no conflicts; supporting material contains the individual disclosures.
Study snapshot
| Design | Randomized placebo-controlled human trial |
|---|---|
| Model | Human participants |
| Sample | 52 randomized; 49 started treatment; 42 completed |
| Intervention | NR 1000 mg/day versus placebo |
| Duration | 12 weeks |
| Endpoints | Cognition; cerebral blood flow; blood NAD+ |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- NR for Brain Health and Alzheimer’s: What the Trials FoundNR for brain health and Alzheimer’s: MCI trial results, pTau217, brain NAD+, perfusion, cognition, combinations and what remains unproven.Read analysis
- Nicotinamide Riboside Benefits: What Human Trials ShowNR benefits assessed through human trials: NAD+, walking, energy, cognition, cardiovascular health, longevity and the latest null findings.Read analysis
- What Is Nicotinamide Riboside? NR Supplements ExplainedWhat is nicotinamide riboside? Understand NR, NAD+, vitamin B3, supplement labels, human evidence and the limits of anti-aging claims.Read analysis
- Best NR Supplements: Evidence, Labels, Testing and ValueBest NR supplements compared through current labels, testing scope, prices and human evidence: DoNotAge, Tru Niagen, Life Extension and Thorne.Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
